Published in Health Business Week, February 27th, 2009
BCD maintains that it did not infringe any patents, and is aware that many of the patent claims in the lawsuit are currently under a final rejection in reexamination proceedings ongoing in the United States Patent and Trademark Office. BCD Semi agreed to settle these patent claims for business reasons. The consent judgment states that BCD Semi voluntarily accepts patent settlement, makes no payment to Power...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
Source: Health Business Week (2009-02-27)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.